

Correction to:
Cancer Biother Radiopharm 2014;29(8):303–309.
DOI: 10.1089/cbr.2014.1653
and Cancer Biother Radiopharm 2014;29(10):451–456.
DOI: 10.1089/cbr.2014.1698

The same error was discovered in two different papers published in the CBR 29/8 October and CBR 29/10 December 2014 issues of *Cancer Biotherapy and Radiopharmaceuticals*. The articles being corrected are:

10.1089/cbr.2014.1653: *si-RNA-Mediated Silencing of ADRBK1 Gene Attenuates Breast Cancer Cell Proliferation* by Zhang C, Chen X, Li Y, Himaya SWA, Wu J, Shi X, Liu X, and Kim S. *Cancer Biother Radiopharm* 2014;29(8):303–309. DOI: 10.1089/cbr.2014.1653.

10.1089/cbr.2014.1698: *Ribosomal Protein S15A Augments Human Osteosarcoma Cell Proliferation In Vitro* by Zhang C, Zhang T, Song E, Himaya SWA, Chen X, and Zheng L. *Cancer Biother Radiopharm* 2014;29(10):451–456. DOI: 10.1089/cbr.2014.1698.

Holly Biotechnologies provided the wrong product specification regarding the siRNA expression vector, lentiviral packing vectors, and the constructed control shRNA plasmid when the authors purchased the shRNA used in these articles.

The incorrectly published shRNA sequence was:

GCGGAGGGTTTGAAAGAATATCTCGAGATATTCTTTCAAACCCTCCGCTTTTTT

The actual—and correct—sequence in the control shRNA plasmid was:

TTCTCCGAACGTGTCACGTCTCGAGACGTGACACGTTCGGAGAATTTTT

Holly Biotechnologies confirmed the wrong control shRNA sequence was only in the product specification. They also confirmed the plasmid was constructed with the correct control shRNA sequence. It did not have any influence on the experimental results.

The online versions of both articles have been corrected.

The authors apologize for this unfortunate circumstance.